1. Home
  2. AKRO vs ABCB Comparison

AKRO vs ABCB Comparison

Compare AKRO & ABCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • ABCB
  • Stock Information
  • Founded
  • AKRO 2017
  • ABCB 1971
  • Country
  • AKRO United States
  • ABCB United States
  • Employees
  • AKRO N/A
  • ABCB N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • ABCB Major Banks
  • Sector
  • AKRO Health Care
  • ABCB Finance
  • Exchange
  • AKRO Nasdaq
  • ABCB Nasdaq
  • Market Cap
  • AKRO 4.5B
  • ABCB 5.1B
  • IPO Year
  • AKRO 2019
  • ABCB N/A
  • Fundamental
  • Price
  • AKRO $54.34
  • ABCB $71.87
  • Analyst Decision
  • AKRO Buy
  • ABCB Buy
  • Analyst Count
  • AKRO 10
  • ABCB 5
  • Target Price
  • AKRO $73.56
  • ABCB $78.00
  • AVG Volume (30 Days)
  • AKRO 1.7M
  • ABCB 445.5K
  • Earning Date
  • AKRO 11-07-2025
  • ABCB 10-27-2025
  • Dividend Yield
  • AKRO N/A
  • ABCB 1.12%
  • EPS Growth
  • AKRO N/A
  • ABCB 20.70
  • EPS
  • AKRO N/A
  • ABCB 5.77
  • Revenue
  • AKRO N/A
  • ABCB $1,130,299,000.00
  • Revenue This Year
  • AKRO N/A
  • ABCB $13.54
  • Revenue Next Year
  • AKRO N/A
  • ABCB $5.13
  • P/E Ratio
  • AKRO N/A
  • ABCB $12.42
  • Revenue Growth
  • AKRO N/A
  • ABCB 7.96
  • 52 Week Low
  • AKRO $21.34
  • ABCB $48.27
  • 52 Week High
  • AKRO $58.40
  • ABCB $76.58
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 68.92
  • ABCB 46.30
  • Support Level
  • AKRO $54.10
  • ABCB $70.55
  • Resistance Level
  • AKRO $54.37
  • ABCB $76.06
  • Average True Range (ATR)
  • AKRO 0.18
  • ABCB 1.91
  • MACD
  • AKRO -0.22
  • ABCB -0.16
  • Stochastic Oscillator
  • AKRO 89.00
  • ABCB 35.34

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About ABCB Ameris Bancorp

Ameris Bancorp is a bank holding company that operates through Ameris Bank, its subsidiary. The company operates branches in Georgia, Alabama, Florida, and South Carolina. It offers traditional banking services such as business banking, personal banking, checking, savings, mobile banking, and others. The bank is organized into four segments: the Banking Division, the Retail Mortgage Division, the Warehouse Lending Division and the Premium Finance Division. The company generates majority of its revenue from the banking division. Ameris intends to acquire banks in its geographic region to increase its market share and expand beyond its current market.

Share on Social Networks: